Dr Scott Mead
Dr Scott Mead graduated from the University of Auckland School of Medicine where he also gained a PhD in Molecular Medicine. His genetic pathology training was undertaken at Christchurch School of Medicine (University of Otago) and the Royal Prince Alfred Hospital, Sydney. Dr Mead has a long-standing interest in cancer genetics, which has seen him work at Great Ormand Street Hospital, London and sabbatical at Harvard Medical School, Boston.
Dr Mead has over five years of experience in diagnostic pharmacogenomics and cancer biomarker applications. He is currently researching the clinical application of personal cancer genome sequencing at the Garvan Institute. Dr Mead is also a Genetic Pathology consultant at Sonic Genetics and a Staff Specialist in Genetic Pathology at St Vincent’s Hospital, Sydney. Dr Mead serves on the Genetic Advisory Committee for the RCPA and is an NATA assessor for molecular genetics laboratory accreditation.
Awards and Honours
Human Genetics Theory (BIOL345) - Macquarie University, 2007
PhD (Molecular Medicine) - University of Auckland, 2002
MBChB - University of Auckland, 2001
BHB - University of Auckland, 1997
MSc Hons (Cell Biology) - University of Auckland, 1987
BSc (Biochemistry) - Massey University, 1983
Chou A, Waddell N, Cowley MJ, Gill AJ, Chang DK, Patch AM, Nones K, Wu J, Pinese M, Johns AL, Miller DK, Kassahn KS, Nagrial AM, Wasan H, Goldstein D, Toon CW, Chin V, Chantrill L, Humphris J, Mead RS, Rooman I, Samra JS, Pajic M, Musgrove EA, Pearson JV, Morey AL, Grimmond SM, Biankin AV. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med. 2013; 5:78-85.
Toon CW, Walsh MD, Chou A, Capper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters RJ, Clendenning M, Rosty C, Young JP, Win AK, Hopper JL, Crook A, von Deimling A, Jenkins MA, Buchanan DD, Gill AJ. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol. 2013; 37:1592-602.
Biankin A.V., Waddell N., Kassahn K.S., Gingras M-C., Johns A.L., et al. Genomic analysis reveals roles for chromatin modification and axon guidance in pancreatic cancer. Nature 2012; 491:399-405.
Lam, E.Y., Chau, J.Y., Kalev-Zylinska, M.L., Fountaine, T.M., Mead, R.S., Hall, C.J., Crosier, P.S., Crosier, K.E., Flores, M.V. Zebrafish Runx1 promoter-EGFP transgenic mark discrete sites of definitive blood progenitors. Blood 2008; 113:1241-49.
Favaloro EJ, Patterson D, Denholm A, Mead S, Gilbert A, Collins A, Estell J, George PM, Smith MP. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. Br J Haematol. 2007; 139:623-6.
Roberts, T., Mead, R.S. and Cowell, J.K. (1996). Characterisation of a human chromosome 1 somatic cell hybrid mapping panel and regional assignment of novel STS. Annals of Human Genetics. 1994; 60:213-20.
Hellsten, E., Versa, J., Heiskanen, M., Makela, T.P., Jarvela, I., Cowell, J.K., Mead, S., Altalo, K., Patotie, A. and Peltonen, L. (1995). Identification of YAC clones for human chromosome 1p32 and physical mapping of the infantile neural ceroid lipofuscinosis (INCL) locus. Genomics 1995; 25:404-12.
Mead, R.S. and Cowell, J.K. (1994). Molecular characterisation of a t(1;10) (p22;q21) constitutional translocation from a patient with neroblastoma. Cancer Genetics and Cytogenetics 1994; 81:151-7.
Vesa, J. Hellsten, E., Barnoski, B.L. Emanuel, B.S. Bilheimer, J.T., Mead, S., Cowell, J.K., Strauss, J.F. and Peltonen, L. (1994). Assignment of sterol carrier protein X to 1p32 and its exclusion as a causative gene for infantile neuronal ceroid lipofuscinosis. Human Molecular Genetics. 1994; 3:341-6.